Head of Molecular Bilogy Department
Field of interest
Molecular medicine, Nutrigenomics, Biotechnology, Natural Products, Molecular Pharmacology.
86 peer-reviewed scientific publications, cited 1663 times, with h-index of 23 (data from Scopus, accessed on 25th of July, 2017).
Selected scientific achievements
1. Identified and characterized molecular mechanisms underlying bioactivities of diverse natural products, including erythrodiol from olive oil, xanthohumol from hops, bilirubin, piperine from black pepper, leoligin from edelweiss, isosilybin A from milk thistle, magnolol and honokiol from Magnolia officinalis, -shogaol from ginger, etc.
2. Elucidated the molecular mechanism determining the reaction direction of the enzyme 11(beta)-hydroxysteroid dehydrogenase (HSD) type 1 (cortisone reductase). 3. Identified diverse new-scaffold agonists of the peroxisome proliferator-activated receptor (PPAR) gamma (clinical target for the treatment of diabetes type 2) and inhibitors of the pro-inflammatory NF-kB signaling pathway.br/> 4. Identified a novel mechanism related to protein stability that is causative for the clinical manifestation of the apparent mineralocorticoid excess (AME) syndrome.br/> 5. Characterized diverse molecular mechanisms and pathways regulating macrophage cholesterol efflux (physiological process of relevance for cardiovascular disease), which might be targeted by small molecules with therapeutic potential.
Realized research projects
1. Principle Investigator (PI) of the project “Increase of macrophage cholesterol efflux by natural products – molecular mechanisms”, funded by the Austrian Science Fund (FWF).
2. Co-PI of the project “EU FP-7 TCM-VASC: Discovery of bioactive natural compounds from Traditional Chinese Medicines used against Cardiovascular Disease”, funded by the European Union Seventh Framework Program (EU FP7).
3. Receiver of a fellowship from Roche Research Foundation (RRF) awarded for the project “NADPH generation in the endoplasmic reticulum - a potential new target in metabolic syndrome and diabetes”.
Organizational activity, dissemination and others
Invited lectures presented at diverse international conferences and institutions. Member of the EU 7th Framework Consortium “Good Practice in TCM Research in the Post-genomic Era”. Member of the Austrian drug discovery consortium “Drugs from nature targeting inflammation (DNTI)”. Reviewer for over 30 scientific journals and project proposal evaluator for several national/international funding institutions. Editor of special issues of several scientific journals (e.g., Biotechnology Advances). Receiver of POENIX Pharmacy Science Award 2011 awarded from PHOENIX group, Mannheim, and of Focus of Excellence Award 2012 awarded from University of Vienna, Austria.
Selected publications and patents
1. Huminiecki L, Horbańczuk J, ATANASOV AG (2017) The functional genomic studies of curcumin. Semin Cancer Biol. Apr 6, 2017. doi: 10.1016/j.semcancer.2017.04.002. PubMed PMID: 28392463. [2016 IF = 9.1].
2. Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, ATANASOV AG, Berindan-Neagoe I. Nutrigenomics in cancer: Revisiting the effects of natural compounds. Semin Cancer Biol. 2017 Jul 1. pii: S1044-579X(17)30171-2. doi: 10.1016/j.semcancer.2017.06.011. PubMed PMID: 28676460. [2016 IF = 9.1].
3. ATANASOV AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv, 2015 Dec;33(8):1582-614. [2016 IF = 10.6].
4. ATANASOV AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ, Odermatt A (2007). Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol 18:1262-1270. [2016 IF = 8.9].
5. ATANASOV AG, Nashev LG, Tam S, Baker ME, Odermatt A (2005). Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ Health Perspect 113(11):1600-6. [2016 IF = 9.8].
PATENT: Use of leoligin derivatives for inhibiting proliferation of smooth muscle cells and as antiinflammatory drug to treat hyperplasia e.g. intimal hyperplasia, stenosis and restenosis, and for coating and impregnating stent and implant (Patent Number: WO2015196228-A1).
Links to professional profiles